)
Astellas Pharma (4503) investor relations material
Astellas Pharma Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 YTD performance and FY2026 outlook
Q2 YTD revenue rose 23% YoY and core operating profit rose 50%, driven by Strategic Brands growth and cost optimization.
FY2026 forecast raised to ¥2,330B revenue and ¥700B core operating profit, with a 30.0% core operating margin.
Strategic Brands FY2026 sales forecast increased by ¥70B to ¥680B; FY2026 SG&A forecast is ¥815B and R&D expense is ¥360B.
Q2 YTD Strategic Brands sales reached ¥333.9B, up 51% YoY; PADCEV sales were ¥158.3B, up 55%.
XTANDI Q2 YTD sales were ¥533.7B, up 12% YoY; sales are expected to decline in 2H due to the US IRA impact.
Growth strategy and profitability targets
FY2026 revenue forecast is ¥2.3T; the outlook targets a pipeline-led inflection from FY2029 and record-high revenue in the mid-2030s.
Strategic Brands target 2x FY2025 sales by FY2030; PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA are the portfolio’s growth brands.
Strategic Brands are projected to exceed 50% of revenue by FY2030, while core operating profit plus R&D is targeted at 50% of revenue.
CSP2026 deliverables include ¥4.3T+ cumulative core operating profit before R&D expense and core operating profit before R&D at 50% of revenue.
Pipeline development
FY2026–30 plans call for 10+ Phase 3 or pivotal study starts, including 5+ by FY2027; pipeline revenue potential is ~¥1T in the mid-2030s.
Pipeline assets are expected to drive growth from FY2029 onward, with R&D base spending averaging 20% of revenue and additional investment of up to 5%.
Setidegrasib Phase 3 studies are ongoing in 1L pancreatic cancer and 2L+ NSCLC, with primary analyses anticipated in FY2029 and FY2028, respectively.
ASP2138 is in a Phase 3 1L gastric/GEJ study; Phase 1 data showed 62.5% unconfirmed ORR in 1L and responses across low-intermediate and high CLDN18.2 expression.
VIR-5500 Phase 1 data in heavily pretreated mCRPC showed 45% ORR among RECIST-evaluable patients; FDA Fast Track designation was granted.
- FY26 margin target pulled forward as pipeline-led growth builds beyond XTANDI.4503
Jefferies Global Healthcare Conference - Strategic Brand growth lifts FY2026 core operating profit guidance to ¥700bn.4503
Q2 2027 - Sustainability efforts and governance reforms are driving measurable enterprise value and innovation.4503
Sustainable Meeting 2024 - Record revenue and profit growth led by strategic brands, pipeline advances, and global expansion.4503
Q1 2027 - Pipeline-led growth, high-margin brands, and oncology innovation to drive record revenues.4503
Jefferies Global Healthcare Conference 2026 - Record revenue and profit growth driven by Strategic Brands and cost optimization, with strong FY2026 outlook.4503
Q4 2026 - Double-digit revenue and profit growth led to upward guidance, driven by strategic brands.4503
Q3 2026 - Core operating profit surged 54.4% on 10.1% revenue growth and strong brand sales.4503
Q2 2026 - Q1 revenue up 26.2% year-on-year, driven by XTANDI and strategic brands, with strong profit growth.4503
Q1 2025
)
)
)
)
)
)
)
)